Empirical Bioscience EB Pure Plasmid Mini-Prep Kit
Empirical Bioscience has launched its new EB Pure Plasmid Mini-Prep Kit, which combines the firm's High-Bind technology with alkaline-SDS lysis of bacterial cells. The kit's High-Bind technology reversibly binds DNA or RNA under optimized conditions, removing proteins and other contaminants. It requires one to five milliliters of bacterial culture and delivers results in less than 30 minutes. It also isolates high-quality plasma or cosmid DNA for extraction up to 10 kilobases and yields up to 20 micrograms per preparation, the firm said.
The kit features an integrated pH indicator within the lysis buffer, which changes color to bright yellow when the lysis buffer reaches the pH level needed for DNA binding. The kit also includes a neutralization buffer, Rnase A, activation buffer, washing buffer, elution buffer, spin columns, and collection tubes. The components create a flexible kit for downstream applications, including automated fluorescent DNA sequencing and restriction enzyme digestion, Empirical added.
ABclonal Technology DNA, RNA Library Prep
ABclonal Technology has launched next-generation sequencing library prep kits for DNA and RNA sequencing, including its Rapid DNA Lib Prep Kit, StepWise DNA kit, and both stranded and non-stranded mRNA library prep kits. The kits are compatible with Illumina sequencing technology and have a 70 percent DNA conversion efficiency with 500 picograms of input, the company said. They range in price from $218 to $558.
Viracor Eurofins CMV Resistance:Letermovir
Viracor Eurofins has launched CMV Resistance:Letermovir, a cytomegalovirus gene sequencing assay for the detection of resistance to Prevymis (letermovir), an antiviral for use in adult hematopoietic stem cell transplant patients. The assay is available as a standalone test or as a complete panel with the other CMV drugs as CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir. Viracor Eurofins said that resistance to Prevymis has not been detected in treatment-naive patients, but noted that clinical trials have shown that resistance can develop in the UL56 gene after exposure for some HSCT patients.
For more new products and services, please visit the New Products page on our website.